NYSE:OGN Organon & Co. (OGN) Stock Price, News & Analysis $8.72 +0.32 (+3.75%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$8.69 -0.03 (-0.29%) As of 08/6/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Organon & Co. Stock (NYSE:OGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organon & Co. alerts:Sign Up Key Stats Today's Range$8.31▼$8.7950-Day Range$8.43▼$10.2052-Week Range$8.01▼$23.10Volume7.30 million shsAverage Volume4.24 million shsMarket Capitalization$2.27 billionP/E Ratio3.24Dividend Yield0.92%Price Target$18.00Consensus RatingModerate Buy Company Overview Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. Read More Organon & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreOGN MarketRank™: Organon & Co. scored higher than 98% of companies evaluated by MarketBeat, and ranked 66th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingOrganon & Co. has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageOrganon & Co. has only been the subject of 2 research reports in the past 90 days.Read more about Organon & Co.'s stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth1.63% Earnings GrowthEarnings for Organon & Co. are expected to grow by 1.63% in the coming year, from $3.68 to $3.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organon & Co. is 3.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Organon & Co. is 3.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.32.Price to Earnings Growth RatioOrganon & Co. has a PEG Ratio of 0.87. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioOrganon & Co. has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.68% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organon & Co. has recently decreased by 7.66%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldOrganon & Co. has a dividend yield of 0.95%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOrganon & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Organon & Co. is 2.78%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Organon & Co. will have a dividend payout ratio of 2.14% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.Read more about Organon & Co.'s dividend. Sustainability and ESG3.7 / 5Environmental Score-2.37 Percentage of Shares Shorted5.68% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organon & Co. has recently decreased by 7.66%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentOrganon & Co. has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Organon & Co. this week, compared to 14 articles on an average week.Search InterestOnly 10 people have searched for OGN on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows4 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Organon & Co. insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,934.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.96% of the stock of Organon & Co. is held by insiders.Percentage Held by Institutions77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organon & Co.'s insider trading history. Receive OGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter. Email Address OGN Stock News HeadlinesOrganon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)August 6 at 5:16 PM | seekingalpha.comOrganon & Co. (OGN) Slashes 13.13% on Disappointing EarningsAugust 6 at 5:16 PM | msn.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Organon (OGN) Fiscal Q2 Revenue Beats 1%August 6 at 2:47 AM | fool.comOrganon & Co. Reports Q2 2025 Financial ResultsAugust 6 at 2:08 AM | tipranks.comOrganon & Co. (OGN) Q2 2025 Earnings Call TranscriptAugust 5 at 1:25 PM | seekingalpha.comOrganon & Co. 2025 Q2 - Results - Earnings Call PresentationAugust 5 at 1:10 PM | seekingalpha.comOrganon Reports Results for the Second Quarter Ended June 30, 2025August 5 at 7:30 AM | businesswire.comSee More Headlines OGN Stock Analysis - Frequently Asked Questions How have OGN shares performed this year? Organon & Co.'s stock was trading at $14.92 at the beginning of the year. Since then, OGN shares have decreased by 41.6% and is now trading at $8.7150. How were Organon & Co.'s earnings last quarter? Organon & Co. (NYSE:OGN) issued its quarterly earnings results on Tuesday, August, 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The business's revenue for the quarter was down .8% compared to the same quarter last year. Read the conference call transcript. Who are Organon & Co.'s major shareholders? Top institutional investors of Organon & Co. include Nordea Investment Management AB (1.89%), Bank of New York Mellon Corp (1.38%), Allianz Asset Management GmbH (0.51%) and KLCM Advisors Inc. (0.47%). Insiders that own company stock include Kevin Ali, Matthew M Walsh, Kirke Weaver and Daniel Karp. View institutional ownership trends. How do I buy shares of Organon & Co.? Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organon & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM). Company Calendar Record date for 6/12 Dividend5/12/2025Ex-Dividend for 6/12 Dividend5/12/2025Dividend Payable6/12/2025Last Earnings8/05/2025Today8/06/2025Record date for 9/11 Dividend8/15/2025Ex-Dividend for 9/11 Dividend8/15/2025Dividend Payable9/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGN CIK1821825 Webwww.organon.com Phone551-430-6900FaxN/AEmployees4,000Year FoundedN/APrice Target and Rating Average Price Target for Organon & Co.$18.00 High Price Target$24.00 Low Price Target$10.00 Potential Upside/Downside+106.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$2.88 Trailing P/E Ratio3.24 Forward P/E Ratio2.37 P/E Growth0.87Net Income$864 million Net Margins11.15% Pretax Margin10.60% Return on Equity182.69% Return on Assets7.06% Debt Debt-to-Equity Ratio16.49 Current Ratio1.67 Quick Ratio1.15 Sales & Book Value Annual Sales$6.40 billion Price / Sales0.35 Cash Flow$5.13 per share Price / Cash Flow1.70 Book Value$1.83 per share Price / Book4.76Miscellaneous Outstanding Shares259,960,000Free Float254,861,000Market Cap$2.27 billion OptionableNot Optionable Beta0.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:OGN) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.